Overview
This book describes the pathologic conditions of drug-induced lung injuries, monitoring strategies, and guides on how to interpret the evidence. It also dives into particular drugs that caused the disorder, such as EGFR inhibitors, anti-EGFR antibodies, mTOR inhibitors, proteasome inhibitors, immune checkpoint inhibitors, neoangiogenesis inhibitors, and other molecular targeted drugs. It outlines the analysis and interpretation of the post-marketing survey on surveillance of each drug for inducing pulmonary lesions presenting diffuse haziness. The data and analysis from this survey are valuable since a guideline is yet to be established due to limited clinical evidence and cases. As new drugs are developed, establishing treatment and event management is crucial. Thus, Drug-induced Pulmonary Disorder in Medical Oncology - Expert Opinion to Decipher Big Data summarizes the accumulated information to provide a foundation for further research advancement. The book offers a refreshing alternative to current approaches to medical oncology and respiratory diseases professionals and will also attract medical affairs members in global pharmaceutical companies.
Full Product Details
Author: Akihiko Gemma
Publisher: Springer Verlag, Singapore
Imprint: Springer Nature
Edition: 2024 ed.
ISBN: 9789819734450
ISBN 10: 9819734452
Pages: 116
Publication Date: 02 August 2024
Audience:
Professional and scholarly
,
Professional & Vocational
Format: Hardback
Publisher's Status: Active
Availability: Manufactured on demand 
We will order this item for you from a manufactured on demand supplier.
Table of Contents
Part I Understanding Drug-Induced Lung Injuries.- 1 Understanding Drug-Induced Lung Injuries.- Part 2 Actual Practice in Drug-Induced Lung Injuries of Each Drug.- 2 EGFR inhibitors (gefitinib, erlotinib, afatinib, osimertinib).- 3 Anti-EGFR antibodies (cetuximab, panitumumab, necitumumab).- 4 mTOR inhibitors (temsirolimus, everolimus).- 5 Proteasome inhibitor (bortezomib).- 6 Immune checkpoint inhibitors (nivolumab, pembrolizumab, atezolizumab, durvalumab).- 7 Neoangiogenesis inhibitors (sunitinib, sorafenib, bevacizumab).- 8 Other molecular targeted drugs (crizotinib, alectinib, etc.).- 9 Antibody-drug conjugates (ADC) (trastuzumab emtansine, trastuzumab deruxtecan).- 10 Anti-cancer drugs (TS-1, taxanes, CPT-11, platinum-containing drugs, etc.).
Reviews
Author Information
Akihiko GemmaPresident, Nippon Medical School 1983: Graduated from the Faculty of Medicine of Nippon Medical School1986: Served as a trainee doctor in the Pathology Department of the National Cancer Center Research Institute1989: Graduated from Nippon Medical School Graduate School1995: Studied at National Cancer Institute of National Institutes of Health (NIH), the United States1998: Appointed as a lecturer to Nippon Medical School2004: Appointed as an associate professor2008: Appointed as a senior professor to the Department of Medicine (Respiratory, Infectious Disease and Oncology Division)2012: Appointed as a professor to the Graduate School of Medicine in charge of respiratory medicine2013: Appointed dean of Department of Medicine2015： Appointed president
Tab Content 6
Author Website:
Customer Reviews
Recent Reviews
No review item found!
Add your own review!
Countries Available
All regions
|
